Loading clinical trials...
Loading clinical trials...
Dual antiplatelet therapy with aspirin and thienopyridines is an essential treatment in patients undergoing percutaneous coronary intervention (PCI). However, despite intensified antiplatelet treatmen...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Beijing Anzhen Hospital
NCT06292117 · Ischemic Stroke, CYP2C19 Polymorphism
NCT06535568 · Coronary Disease, Heart Diseases, and more
NCT06075420 · Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
NCT07398001 · Percutaneous Coronary Intervention, Antiplatelet Therapy, and more
NCT07238764 · High Bleeding Risk Patients, DAPT(Dual Antiplatelet Therapy), and more
Beijing Anzhen Hospital
Beijing, Beijing Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions